400 related articles for article (PubMed ID: 33934588)
1. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events.
Kobayashi T; Iwama S; Arima H
Endocr J; 2024 Jan; 71(1):23-29. PubMed ID: 37940567
[TBL] [Abstract][Full Text] [Related]
3. [Endocrine Dysfunction Associated with Immune Checkpoint Blockade].
Iwama S
Gan To Kagaku Ryoho; 2020 Feb; 47(2):203-206. PubMed ID: 32381947
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
5. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society.
Arima H; Iwama S; Inaba H; Ariyasu H; Makita N; Otsuki M; Kageyama K; Imagawa A; Akamizu T
Endocr J; 2019 Jul; 66(7):581-586. PubMed ID: 31243183
[TBL] [Abstract][Full Text] [Related]
6. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
7. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
[No Abstract] [Full Text] [Related]
8. Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers.
Kotwal A; Ryder M
Curr Opin Endocrinol Diabetes Obes; 2021 Oct; 28(5):517-524. PubMed ID: 34269714
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
10. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
Stelmachowska-Banaś M; Czajka-Oraniec I
Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
12. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Daban A; Gonnin C; Phan L; Saldmann A; Granier C; Lillo-Lelouet A; Le Beller C; Pouchot J; Weiss L; Tartour E; Fabre E; Medioni J; Oudard S; Vano YA; Dragon-Durey MA; Simonaggio A
Oncoimmunology; 2023; 12(1):2204754. PubMed ID: 37187974
[TBL] [Abstract][Full Text] [Related]
13. Endocrine toxicities of immune checkpoint inhibitors.
Wright JJ; Powers AC; Johnson DB
Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
[TBL] [Abstract][Full Text] [Related]
14. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
[TBL] [Abstract][Full Text] [Related]
15. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors.
Kobayashi T; Iwama S; Sugiyama D; Yasuda Y; Okuji T; Ito M; Ito S; Sugiyama M; Onoue T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Nishikawa H; Arima H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011534
[TBL] [Abstract][Full Text] [Related]
16. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
17. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
Trevisani V; Iughetti L; Lucaccioni L; Predieri B
Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
[TBL] [Abstract][Full Text] [Related]
18. Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.
Wright JJ; Johnson DB
J Clin Endocrinol Metab; 2023 May; 108(6):1514-1525. PubMed ID: 36481794
[TBL] [Abstract][Full Text] [Related]
19. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
20. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]